Compare Regeneron Pharmaceuticals Inc (REGN) vs Teucrium Soybean Fund (SOYB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Regeneron Pharmaceuticals Inc vs Teucrium Soybean Fund — how do they compare? Regeneron Pharmaceuticals Inc trades at $652.76 (market cap $70.79B), while Teucrium Soybean Fund trades at $26.11. The key difference: Regeneron Pharmaceuticals Inc pays a 0.56% dividend while Teucrium Soybean Fund pays none, and Teucrium Soybean Fund is trading nearer its 52-week high, Regeneron Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| REGN | SOYB | |
|---|---|---|
Market Cap | $70.79B | — |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $812.27 | $25.88 |
52-Week Low | $545.46 | $21.07 |
Enterprise Value | $64.74B | — |
Dividend Yield | 0.56% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Regeneron Pharmaceuticals (REGN) trades at $675.19, down 0.22% on the day, with a bullish technical signal from moving averages. The company shows strong fundamentals with a P/E of 16.41, net income margin of 29.65%, and consistent earnings beats in recent quarters. However, sentiment is clouded by a securities class action lawsuit related to a Phase 3 clinical trial failure disclosed in July 2026.
The outlook remains positive based on analyst consensus with a $764.50 price target and 69% buy ratings, but near-term volatility is likely due to legal overhangs. Investment opportunity lies in robust profitability and growth prospects, while key risks include litigation outcomes and clinical trial setbacks.
SOYB trades at $25.88, up 1.53% today, with a bullish technical outlook supported by moving averages. The stock shows strong momentum indicators but lacks available financial ratio data. Recent news highlights potential tailwinds from China's $17 billion U.S. crop purchase pledge through 2028, which may benefit agricultural sector stocks.
The stock's outlook is cautiously optimistic due to positive technical signals and favorable sector news, but investment is tempered by absent fundamental metrics and reliance on broader agricultural market trends. Key risks include commodity price volatility and execution uncertainties in trade agreements.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →About Teucrium Soybean Fund
SOYB is a commodity ETF that provides exposure to the price of soybean futures. It utilizes a laddered strategy by investing in several benchmark futures contracts to reduce the impact of roll costs and contango in the agricultural market.
Read more on SOYB →
